Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that in vitro exposure to dihydrotestosterone worsened COVID-19 spike protein-induced endothelial injury, while spironolactone showed potential in reducing this effect, suggesting a rationale for further evaluation in treating COVID-19.

In this study, researchers linked SARS-CoV-2 infection to telogen effluvium in some COVID-19 patients by observing the accumulation of viral proteins in hair follicle cells, which may trigger stress responses and cell death, suggesting hair follicles as a potential target in COVID-19.

This study found that specific mutations in the spike protein of SARS-CoV-2 may significantly alter its structure and affect how it binds to certain inhibitors, but experimental studies are needed to confirm potential clinical implications.

This study found that mRNA booster vaccinations for SARS-CoV-2 increased protective antibodies without worsening autoimmune disease activity in patients with pemphigus and bullous pemphigoid.

This study found that healthcare workers with a positive COVID-19 test reported long COVID symptoms more frequently than negative controls, while prior physical activity was linked to reduced neurocognitive and fatigue symptoms.

This review explores the impact of COVID-19 on skin appendages beyond COVID-toes, highlighting hair and nail disorders in affected individuals, but provides no new clinical results.

This review discusses the dual role of the TMPRSS2 gene in coronaviral lung infection and prostate cancer, cautioning against TMPRSS2 inhibitors for early prostate cancer due to potential pro-inflammatory effects.

This review synthesizes existing evidence on the link between androgenic alopecia and severe COVID-19 outcomes, noting a potential role for anti-androgenic therapies in treating SARS-CoV-2 infections.

This review explores the role of the TMPRSS2 gene in facilitating SARS-CoV-2 infection and its potential as a therapeutic target in COVID-19 and other respiratory infections, highlighting challenges in developing selective inhibitors.

This article reviews the structure, genomic organization, and pathogenesis of SARS-CoV-2 and discusses current efforts in prevention and treatments for COVID-19 without reporting new clinical results.

This study suggests that finasteride might reduce SARS-COV-2 infectivity by inducing epigenetic changes in the TMPRss2 protein, which is crucial for viral activation and multiplication.

This study found that SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize its RNA and enhance translation, and identified Cepharanthine and Trifluoperazine as potential treatments against the virus.

This review discusses the functions of SARS-CoV-2 non-structural proteins in facilitating immune evasion and highlights possible therapeutic strategies, reporting no new clinical results.

This study suggests that women with polycystic ovary syndrome may have an increased risk of COVID-19-related cardiac and renal complications, and that weight loss through lifestyle changes could help reduce these risks.

This study reported that COVID-19 patients treated with nirmatrelvir/ritonavir had lower anti-spike IgG levels and different cytokine patterns compared to those not receiving antiviral treatment, suggesting early antiviral use may alter immune response by reducing viral load and antigen presentation.

This article discusses the potential mechanism by which 5α-reductase inhibitors might offer protection against SARS-CoV-2, emphasizing possible roles of dehydroepiandrosterone and its impact on nitric oxide bioavailability, but reports no new experimental results.

This study observed that male sex, diabetes mellitus, and high maximum C-reactive protein levels during the acute phase of COVID-19 were linked to elevated anti-SARS-CoV-2 antibody levels.

This review highlights phytochemicals, particularly flavonoids and phenolics, as potential supportive treatments for SARS-CoV-2 by interfering with viral proteins and providing anti-inflammatory effects; it suggests a foundation for future therapeutic and vaccine development efforts.

This study found that the antiandrogen drug enzalutamide reduced TMPRSS2 levels and significantly decreased SARS-CoV-2 entry and infection in lung cells, supporting further clinical trials for COVID-19 treatment.

This study used bioinformatics to explore molecular differences in testicular and ovarian responses to SARS-CoV-2, identifying genes that could be associated with sex differences in infection outcomes.

This study explores how SARS-CoV-2 interacts with endocrine organs and highlights specific endocrine molecules that help explain the progression and outcomes of COVID-19, especially in patients with certain metabolic conditions.

In this study, researchers developed a rapid platform using primary human lung tissues to identify SARS-CoV-2 targets and test antiviral compounds, achieving highly reproducible results across viral variants.

In this study, cepharanthine and tetrandrine demonstrated efficacy against SARS-CoV-2 in a cell-based infection assay, with cepharanthine showing a lower IC50 value.

This molecular docking study reported that danoprevir, remdesivir, and saridegib exhibit stronger binding affinities to the main protease of SARS-CoV-2 than the control, suggesting their potential as inhibitors of the virus's replication process.

This study reviews the mechanisms by which SARS-CoV-2 may impact male fertility, noting potential disruptions in spermatogenesis and hormone secretion, and underscores the need for follow-up in recovered men.

This review discusses the impact of COVID-19 on the endocrine system and reports no clinical results; the authors emphasize the need to investigate endocrine damage during and after COVID-19 infection.

This study found that ACE2 and TMPRSS2 genes were more highly expressed in tumors of elderly male cancer patients compared to healthy individuals, with notable differences across age and gender.

In this study, researchers reported that a newly developed interferon-γ release assay for cell-mediated immunity to SARS-CoV-2 nucleocapsid peptides demonstrated high sensitivity and specificity, making it a robust tool for routine diagnostic tests and potentially useful in predicting clinical outcomes after pathogen re-exposure.

This review explores whether SARS-CoV-2 could trigger or worsen α-synucleinopathies, like Parkinson's disease, by affecting α-synuclein misfolding and aggregation, potentially linking COVID-19 with the development of parkinsonism-like symptoms.

This review discusses the transmission and immune response of SARS-CoV-2 and highlights ongoing research for developing vaccines and antiviral treatments, but it presents no new clinical findings.